Generally, TNF-α inhibitors are considered to display safe pharmacological profiles, being assessed even during pregnancy, where they cross the placenta starting from the 22nd gestational week [15], as well as during the COVID-19 epidemic, where patients under treatment with TNF-α inhibitors exhibited lower rates of morbidity and mortality related to the viral infection compared to the general population [16]. The gene discussed is TNF; the disease is viral infectious disease.